血清肿瘤标志物与非小细胞肺癌驱动基因突变发生率的相关性分析

祝梦晓; 胡晨; 何勇

doi:10.16016/j.2097-0927.202209136

您当前的位置：

首页 >

文章列表页 >

血清肿瘤标志物与非小细胞肺癌驱动基因突变发生率的相关性分析

专题报道：肺癌靶向治疗 | 更新时间：2026-01-09

- 血清肿瘤标志物与非小细胞肺癌驱动基因突变发生率的相关性分析
- Correlation of serum tumor markers and incidence of driver gene mutations in non-small cell lung cancer
- 陆军军医大学学报 2022年44卷第24期页码：2465-2473
- 作者机构：
  
  400042 重庆，陆军特色医学中心呼吸与危重症医学科
- 作者简介：
  
  [ 何勇，E-mail: heyong@tmmu.edu.cn HE Yong, E-mail: heyong@tmmu.edu.cn
- 基金信息：
  
  国家自然科学基金面上项目(81972189)
- DOI：10.16016/j.2097-0927.202209136
  中图分类号： R394.3;R730.43;R734.2
- 收稿：2022-09-15，
  
  修回：2022-10-17，
  
  纸质出版：2022-12-30
- 稿件说明：
移动端阅览
祝梦晓, 胡晨, 何勇. 血清肿瘤标志物与非小细胞肺癌驱动基因突变发生率的相关性分析[J]. 陆军军医大学学报, 2022,44(24):2465-2473.

Mengxiao ZHU, Chen HU, Yong HE. Correlation of serum tumor markers and incidence of driver gene mutations in non-small cell lung cancer[J]. Journal of Army Medical University, 2022, 44(24): 2465-2473.
祝梦晓, 胡晨, 何勇. 血清肿瘤标志物与非小细胞肺癌驱动基因突变发生率的相关性分析[J]. 陆军军医大学学报, 2022,44(24):2465-2473. DOI： 10.16016/j.2097-0927.202209136.

Mengxiao ZHU, Chen HU, Yong HE. Correlation of serum tumor markers and incidence of driver gene mutations in non-small cell lung cancer[J]. Journal of Army Medical University, 2022, 44(24): 2465-2473. DOI： 10.16016/j.2097-0927.202209136.

摘要

目的

探讨血清肿瘤标志物与非小细胞肺癌(non-small cell lung cancer，NSCLC)驱动基因突变与否是否存在相关性，为血清肿瘤标志物指导NSCLC靶向治疗提供参考。

方法

本研究采用横断面研究设计，自2015年12月到2021年3月，回顾性纳入陆军特色医学中心呼吸科、肿瘤科、胸外科共1 008例行组织活检以及驱动基因检测的NSCLC患者。收集患者的临床资料、血清肿瘤标志物以及肺癌基因检测结果，通过相关性分析和受试者工作特征曲线(receiver operating characteristic curve，ROC)评价多种驱动基因突变与患者临床特征或特定血清肿瘤标志物的相关性。并根据肿瘤标志物升高的水平以及是否具备手术指针进行分组分析，观察不同分组患者驱动基因突变类型及突变率的差别。

结果

本研究纳入1 008例患者中男性674例，女性334例，平均年龄58.4岁。驱动基因突变的总发生率为64.5%。其中，血清癌胚抗原(carcinoembryonic antigen，CEA)升高(49.9%

.32.6%，

0.001)和细胞角蛋白19的可溶性片段(cytokeratin fragment 19，CYFRA21-1)未升高(48.5%

.38.3%，

=0.003)患者的表皮生长因子受体(epidermal growth factor receptor，

EGFR

)基因突变发生率较高。与此同时，

EGFR

突变患者的血清CEA水平显著高于

EGFR

野生型患者[12.19(3.49，79.05)

. 4.93(2.47，17.29) ng/mL，

0.001

]

。随着血清CEA的升高，

EGFR

突变发生率逐渐增高。分层分析显示：在Ⅰ~ⅢA期患者中，

EGFR

突变患者的血清CEA水平与野生型患者无差异。血清神经元特异性烯醇化酶(neuron-specific enolase，NSE)异常升高的患者较NSE正常水平患者发生鼠类肉瘤病毒癌基因(kirsten rat sarcoma viral oncogene，

KRAS

)基因突变的可能性更大。

结论

NSCLC患者血清CEA水平与

EGFR

突变发生存在相关性；尤其是在ⅢB~Ⅵ期肺癌患者中，血清CEA水平越高的患者

EGFR

的突变率越高，提示在CEA明显升高的晚期肺癌患者更应推荐行肺癌基因检测评，明确是否具有靶向治疗指征。

Abstract

Objective

To explore the correlation between serum tumor markers and mutations of driver genes in non-small cell lung cancer (NSCLC) patients

so as to provide references for serum tumor markers-guided targeted therapies for NSCLC.

Methods

A cross-sectional study was performed on 1 008 NSCLC patients admitted in the respiratory

oncology and thoracic surgery departments of our medical center from December 2015 to March 2021. All these patients underwent tissue biopsies and driver gene tests. Their clinical data and results of serum tumor markers and lung cancer-specific gene test were collected. The correlation of mutations of driver genes with clinical characteristics and serum tumor markers were analyzed with correlation analysis and receiver operating characteristic (ROC) curve analysis. Then the patients were grouped according to the elevated levels of these tumor markers and presence of surgical indicators or not. The differences in mutation types and rates in the driver genes were observed among different groups of patients.

Results

In the 1 008 patients

there were 674 males and 334 females

with an average age of 58.4 years. The total incidence of driver gene mutations was 64.5%. Higher mutation rate of epidermal growth factor receptor (

EGFR

) was observed in the patients with increased serum carcinoembryonic antigen (CEA) level than those without (49.9%

32.6%

0.001) and in the patients with unraised cytokeratin fragment 19 (CYFRA21-1) level than those with unchanged or elevated level (48.5%

38.3%

=0.003). And

the serum CEA level was significantly higher in the

EGFR

mutant patients than those with

EGFR

wild-type [12.19 (3.49~79.05)

4.93 (2.47~17.29) ng/mL

0.001

]

. With the increase of serum CEA level

the occurrence of

EGFR

mutations was gradually increased. Stratified analysis showed that in stage ⅢB to Ⅵ patients

the serum CEA level was obviously higher in patients with

EGFR

mutation than those with

EGFR

wild-type. The patients with abnormally elevated serum neuron-specific enolase (NSE) level showed higher mutation rate of kirsten rat sarcoma viral oncogene (

KRAS

)

than those with normal NSE level.

Conclusion

In NSCLC patients

serum CEA level is correlated with occurrence of

EGFR

mutations. Especially for those with stage ⅢB to Ⅵ

higher serum CEA level indicates higher mutation rate of

EGFR

. Lung cancer-specific gene test should be recommended to carry out in advanced lung cancer patients with significantly elevated CEA in order to determine whether there are indications for target therapy.

关键词

Keywords

references

SUNG H, FERLAY J, SIEGEL R L, et al . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J ] . CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.

HIRSCH F R, SCAGLIOTTI G V, MULSHINE J L, et al . Lung cancer: current therapies and new targeted treatments[J ] . Lancet, 2017, 389(10066): 299-311. DOI: 10.1016/S0140-6736(16)30958-8.

TAN C S, KUMARAKULASINGHE N B, HUANG Y Q, et al . Third generation EGFR TKIs: current data and future directions[J ] . Mol Cancer, 2018, 17(1): 29. DOI: 10.1186/s12943-018-0778-0.

FUKUI T, TACHIHARA M, NAGANO T, et al . Review of therapeutic strategies for anaplastic lymphoma kinase-rearranged non-small cell lung cancer[J ] . Cancers, 2022, 14(5): 1184. DOI: 10.3390/cancers14051184.

URAS I Z, MOLL H P, CASANOVA E. Targeting KRAS mutant non-small-cell lung cancer: past, present and future[J]. Int J Mol Sci, 2020, 21(12): 4325. DOI: 10.3390/ijms21124325.

HOSEOK I, CHO J Y. Lung cancer biomarkers[J]. Adv Clin Chem, 2015, 72: 107-170. DOI: 10.1016/bs.acc.2015.07.003.

FENG L X, WANG J, YU Z, et al . Clinical significance of serum EGFR gene mutation and serum tumor markers in predicting tyrosine kinase inhibitor efficacy in lung adenocarcinoma[J ] . Clin Transl Oncol, 2019, 21(8): 1005-101 3. DOI: 10.1007/s12094-018-02014-6..

ZHAO C, LI J, ZHANG Y, et al . The rational application of liquid biopsy based on next-generation sequencing in advanced non-small cell lung cancer[J ] . Cancer Med, 2022, Nov 7. DOI: 10.1002/cam4.5410.

LIU J, ZHAO Y Q, HAN X, et al . Correlation between pre-treatment serum carcinoembryonic antigen levels and genotypes in a large population of Chinese people with advanced lungadenocarcinoma[J ] . Intern Med J, 2019, 49(5): 634-643. DOI: 10.1111/imj.14152.

WANG S F, MA P, MA G Z, et al . Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: a retrospective analysis[J ] . Eur J Cancer, 2020, 124: 1-14. DOI: 10.1016/j.ejca.2019.10.005.

GRIMES D A, SCHULZ K F. An overview of clinical research: the lay of the land[J]. Lancet, 2002, 359(9300): 57-61. DOI: 10.1016/S0140-6736(02)07283-5.

LEE B, LEE T, LEE S H, et al . Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6, 595 lung cancers[J ] . Oncotarget, 2016, 7(17): 23874-23884. DOI: 10.18632/oncotarget.8074.

BENCHIMOL S, FUKS A, JOTHY S, et al . Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule[J ] . Cell, 1989, 57(2): 327-334. DOI: 10.1016/0092-8674(89)90970-7.

WIRTH T, SOETH E, CZUBAYKO F, et al . Inhibition of endogenous carcinoembryonic antigen (CEA) increases the apoptotic rate of colon cancer cells and inhibits metastatic tumor growth[J ] . Clin Exp Metastasis, 2002, 19(2): 155-160. DOI: 10.1023/a:1014566127493.

ORDOÑEZ C, SCREATON R A, ILANTZIS C, et al . Human carcinoembryonic antigen functions as a general inhibitor of anoikis[J ] . Cancer Res, 2000, 60(13): 3419-3424.

SORDELLA R, BELL D W, HABER D A, et al . Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways[J ] . Science, 2004, 305(5687): 1163-1167. DOI: 10.1126/science.1101637.

CAPPUZZO F, MAGRINI E, CERESOLI G L, et al . Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer[J ] . J Natl Cancer Inst, 2004, 96(15): 1133-1141. DOI: 10.1093/ jnci/djh217.

KOBAYASHI M, TAKEUCHI T, OHTSUKI Y. Establishment of three novel human malignant pleural mesothelioma cell lines: morphological and cytogenetical studies and EGFR mutation status[J]. Anticancer Res, 2008, 28(1A): 197-208.

孙宇晶, 刘畅, 龙彦, 等. NSCLC患者治疗前血清CEA和CYFRA21-1水平与EGFR突变及EGFR-TKI疗效的关系[J]. 中华检验医学杂志, 中华检验医学杂志, 2015, 38(6) : 407-411. DOI: 10.3760/cma.j.issn.1009-9158.2015.06.011.

SUN Y J, LIU C, LONG Y, et al . Serum CEA and CYFRA21-1 correlates with EGFR mutation and EGFR-TKI effectiveness in untreated NSCLC patients[J ] . Chin J Lab Med, 2015, 38(6): 407-411. DOI: 10.3760/cma.j.issn.1009-9158.2015.06.011.

TANAKA K, HATA A, KAJI R, et al . Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation[J ] . J Thorac Oncol, 2013, Jul; 8(7): 892-898. doi: 10.1097/JTO.0b013e31828c3929.

JUNG M, KIM S H, LEE Y J, et al . Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib[J ] . Exp Ther Med, 2011, 2(4): 685-693. DOI: 10.3892/etm.2011.273.

BLACKHALL F H, PETERS S, BUBENDORF L, et al . Prevalence and clinical outcomes for patients with ALK-positive resected stage Ⅰ to Ⅲ adenocarcinoma: results from the European thoracic oncology platform lungscape project[J ] . J Clin Oncol, 2014, 32(25): 2780-2787. DOI: 10.1200/jco.2013.54.5921.

HANAGIRI T, SUGAYA M, TAKENAKA M, et al . Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer[J ] . Lung Cancer, 2011, 74(1): 112-117. DOI: 10.1016/j.lungcan.2011.02.001.

PAIK J H, CHOI C M, KIM H, et al . Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma[J ] . Lung Cancer, 2012, 76(3): 403-409. DOI: 10.1016/j.lungcan.2011.11.008.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

融合深度学习、临床与影像组学特征的综合模型提升非小细胞肺癌EGFR突变预测效能

载阿霉素的重楼皂苷脂质体制备及其体外协同抗非小细胞肺癌的活性研究

基于机器学习的多模态数据建立Ⅰ期非小细胞肺癌患者术后复发预测模型

表皮生长因子受体酪氨酸激酶抑制剂在非小细胞肺癌治疗的研究进展及展望